Sweden · Delayed Price · Currency is SEK Active Biotech AB Company Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden.
It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors.
The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center.
The company was incorporated in 1983 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Helen Tuvesson |
Contact Details
Address: ScheelevAegen 22 Lund, 223 63 Sweden | |
| Phone | 46 46 19 20 00 |
| Website | activebiotech.com |
Stock Details
| Ticker Symbol | ACTI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0001137985 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Helen Tuvesson Ph.D. | President and Chief Executive Officer |
| Hans Kolam | Chief Financial Officer |
| Dr. Erik Vahtola M.D., Ph.D. | Chief Medical Officer |